[Skip to Navigation]
September 1981

Ac2IDU, BVDU, and Thymine Arabinoside Therapy in Experimental Herpes Keratitis

Author Affiliations

From the Department of Cornea Research, Eye Research Institute of Retina Foundation (Drs Hettinger, Pavan-Langston, and Park), and the Department of Ophthalmology, Harvard Medical School (Drs Hettinger, Pavan-Langston, Park, and Albert), Boston; the Rega Institute for Medical Research, University of Leuven, Belgium (Dr De Clercq); and the Department of Pharmacology, Yale University School of Medicine, New Haven, Conn (Dr Lin). Dr Hettinger is now with the University of Kansas, Kansas City.

Arch Ophthalmol. 1981;99(9):1618-1621. doi:10.1001/archopht.1981.03930020492020

• The therapeutic efficacy of three new antiviral agents—5-iodo-3',5'-diacetyl-2-deoxyuridine (diacetylidoxuridine, 1% Ac2IDU), E-5-(2-bromovinyl)-2'-deoxyuridine (0.25% BVDU), and 3% thymine arabinoside—is compared with available antivirals in an experimental model of herpes simplex virus type 1 (HSV-1) keratitis in New Zealand white rabbits. Compared with placebo, Ac2IDU significantly reduced ulcerative keratitis on days 4 through 8 after inoculation with virus and iritis on day 8 after inoculation. Compared with placebo, thymine arabinoside reduced ulcerative keratitis but not significantly. Thymine arabinoside caused significant iritis in all eyes. The epithelial disease in BVDU-treated eyes was significantly less than that in placebo-treated eyes on days 5 through 8 after inoculation. The results indicate that 1% Ac2 IDU and 0.25% BVDU were effective in our ocular model of HSV-1 keratitis, whereas thymine arabinoside was not.

Add or change institution